Invention Grant
US08642034B2 Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
有权
使用TGF-β拮抗剂治疗发生支气管肺发育不良的风险的婴儿
- Patent Title: Use of TGF-β antagonists to treat infants at risk of developing bronchopulmonary dysplasia
- Patent Title (中): 使用TGF-β拮抗剂治疗发生支气管肺发育不良的风险的婴儿
-
Application No.: US12444059Application Date: 2007-10-03
-
Publication No.: US08642034B2Publication Date: 2014-02-04
- Inventor: James B. Streisand , Jesse D. Roberts, Jr.
- Applicant: James B. Streisand , Jesse D. Roberts, Jr.
- Applicant Address: US MA Cambridge
- Assignee: Genzyme Corporation
- Current Assignee: Genzyme Corporation
- Current Assignee Address: US MA Cambridge
- Agency: Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
- International Application: PCT/US2007/021234 WO 20071003
- International Announcement: WO2008/060371 WO 20080522
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K38/17 ; C07K16/22 ; C07K16/28 ; C07K14/495 ; C07K14/71 ; C07K14/785
Abstract:
The disclosure relates to methods of treating an infant at risk of developing bronchopulmonary dysplasia, including premature infants, by administering a TGF-β antagonist during the perinatal period, including the prenatal period and/or the postnatal period. For administration during the prenatal period, the TGF-β antagonist can be administered either directly to the infant in utero, or indirectly by administration to the mother.
Public/Granted literature
- US20100008911A1 USE OF TGF-BETA ANTAGONISTS TO TREAT INFANTS AT RISK OF DEVELOPING BRONCHOPULMONARY DYSPLASIA Public/Granted day:2010-01-14
Information query
